Skip to content

GTC’s Orphan Drugs Research And Commercialization Conference

April 9, 2013

Philip Astley-Sparke, who was recently appointed President U.S. of uniQure B.V., will give the featured presentation, “Is Gene Therapy About to Deliver for the Investor?” at GTC’s Orphan Drugs Research & Commercialization Conference. uniQure’s Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, became the first approved gene therapy in the Western world when it was approved by the European Union in November 2012. Mr. Astley-Sparke will discuss why gene therapy is now ready for prime time and how marketable such an expensive treatment is for rare disease patients

GTC is proud to announce the Orphan Drugs Research & Commercialization Conference on May 8-10, 2013 in Boston, MA. This meeting provides opportunities for industry leaders, members of academia, government regulators, and patient groups to dialogue about strategies to improve orphan drug research, pricing, reimbursement, access, and other key topics.

Keynote speakers include Steve Groft, the Director of the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH), and Michael Scott, Chairman of the Board of Directors at the National Organization for Rare Disorders (NORD). For an updated speaker list, click here.

May 8-10, 2013 | Boston, MA | Further information  
Register today and get the exclusive $180 discount!

Please Note: The Orphan Druganaut Blog is a Media Partner.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: